MK-6070 (HPN328-4001)

· Harpoon Therapeutics, Inc. (a subsidiary of Merck & Co.)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-6070 (HPN328-4001), covering 2026-02-24 to 2026-02-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) [Phase 1, Phase 2]

See pricing